To keep patients on amyloid immunotherapy safe, doctors need to be able to spot subtle signs of ARIA on MRI scans. For memory clinics that have limited experience with these therapies, this may prove ...

Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

Move Over, Vial. In a new titra/news/conference-coverage/donanemab-small-tweak-titration-big-gain-safetytion protocol (bottom ...

Lecanemab has been in clinical use in the U.S. for nearly two years, and in Japan for not quite a year. How is it going? At the Clinical Trials on Alzheimer’s Disease conference, held October 29 ...

“Bruce had a brilliant career in both academia and industry and left an indelible mark on the Alzheimer’s disease drug ...

The fifth time may be the charm for antibodies targeting tau. At the 16th Clinical Trials on Alzheimer’s Disease conference, held October 29 to November 1 in Madrid, Brussels-based UCB Pharma ...

In recent years, CryoEM has enabled scientists to decipher the structures of the fibrils that form various deposits in neurodegenerative disease. They have not only solved disease-specific folding ...